Gilead Sciences, Inc. (GILD) Stock Price Today
Aura AI Summary
Key Stats
- $162.98BMARKET_CAP
- -VOLUME
- HealthSECTOR
- $155.80FIFTY_TWO_WEEK_HIGH
- $108.22FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $177.51BENTERPRISE_VALUE
- 2.5%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Gilead Sciences, Inc. (GILD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $108.22 and a high of $155.8, highlighting its annual price range. Buy and sell Gilead Sciences, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Most Recent News
Global infant heart monitor market to reach $7.93B by 2035 with 10.85% CAGR, driven by tech advances and home care demand
The global infant heart monitor market, valued at $2.83 billion in 2025, is projected to grow to $7.93 billion by 2035 at a CAGR of 10.85%. Growth is fueled by advances in wearable and wireless monitoring technologies, increased adoption of home care...

Halper Sadeh LLC probes fairness of major company sales for shareholders' benefit.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...

Europe approves TEPKINLY combo for relapsed follicular lymphoma, offering a chemo-free treatment option.
The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for se...
